In two of the remaining four samples, that is, in two out of ten cases (20%), the Philadelphia-negative MPN diagnosis was questioned based on a negative result for JAK2, MPL and CALR and the centers were suggested to review the cases. This evidence concerns the gene JAK2 and myeloproliferative disorder.